

## Partnerships to develop POC diagnostic tests

**January 2015—Chembio Diagnostics announced it has entered into an exclusive agreement** with Integrated BioTherapeutics, a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. Under the terms of the agreement, Chembio will combine its patented Dual Path Platform technology with IBT's proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness. Chembio will have exclusive rights to any POC product developed through this agreement.

Chembio has also entered into two other agreements—one to develop a POC diagnostic test for dengue fever virus and another to develop, with an international diagnostics company, a POC diagnostic test for a type of cancer. Both development projects will incorporate Chembio's DPP technology. Under the terms of the agreements, financial details and the names of the collaborators are not being disclosed.

[\*\*\*Chembio Diagnostics\*\*\*](#), 844-243-6246